Esperion Therapeutics (NASDAQ:ESPR) Posts Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• Esperion Therapeutics missed quarterly expectations, reporting EPS of -$0.10 versus the consensus estimate of -$0.04, and revenue of $80.1 million versus expectations of $84.52 million.
• The stock was unchanged at $3.14 following the earnings release, with trading volume below its average for the day.
• Analyst sentiment has weakened, as several firms recently downgraded the stock and MarketBeat data now shows a consensus rating of “Hold” with a $5.54 price target.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06), FiscalAI reports. The company had revenue of $80.10 million for the quarter, compared to analysts' expectations of $84.52 million.

Esperion Therapeutics Price Performance

NASDAQ ESPR remained flat at $3.14 during trading hours on Friday. 7,422,727 shares of the company traded hands, compared to its average volume of 8,629,511. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.18. The company has a market cap of $808.25 million, a P/E ratio of -18.47, a PEG ratio of 2.56 and a beta of 0.91. The company's 50-day moving average is $2.53 and its 200-day moving average is $3.09.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ESPR. Needham & Company LLC lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Monday. Weiss Ratings reissued a "sell (d-)" rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. HC Wainwright lowered Esperion Therapeutics from a "buy" rating to a "neutral" rating and set a $3.16 price objective on the stock. in a report on Friday, May 1st. Piper Sandler lowered shares of Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, May 1st. Finally, Cantor Fitzgerald downgraded shares of Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $5.54.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp acquired a new position in Esperion Therapeutics during the first quarter worth $278,000. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics during the 2nd quarter worth approximately $25,000. Geode Capital Management LLC boosted its position in Esperion Therapeutics by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company's stock valued at $4,513,000 after buying an additional 137,691 shares during the period. Rhumbline Advisers grew its stake in shares of Esperion Therapeutics by 16.8% in the second quarter. Rhumbline Advisers now owns 275,688 shares of the biopharmaceutical company's stock worth $271,000 after acquiring an additional 39,658 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Esperion Therapeutics by 93.3% during the 2nd quarter. Invesco Ltd. now owns 493,929 shares of the biopharmaceutical company's stock worth $486,000 after purchasing an additional 238,449 shares during the period. Hedge funds and other institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.